| __timestamp | Dyne Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 5758000 |
| Thursday, January 1, 2015 | 2028000000 | 8423000 |
| Friday, January 1, 2016 | 2281000000 | 11986000 |
| Sunday, January 1, 2017 | 2932000000 | 15215000 |
| Monday, January 1, 2018 | 24000 | 15356000 |
| Tuesday, January 1, 2019 | 271000 | 16660000 |
| Wednesday, January 1, 2020 | 700000 | 52459000 |
| Friday, January 1, 2021 | 1088000 | 75061000 |
| Saturday, January 1, 2022 | 3345000 | 87221000 |
| Sunday, January 1, 2023 | 2461000 | 83779000 |
Cracking the code
In the ever-evolving landscape of biopharmaceuticals, understanding cost structures is crucial. Supernus Pharmaceuticals, Inc. and Dyne Therapeutics, Inc. offer a fascinating case study. From 2014 to 2023, Supernus Pharmaceuticals saw a steady increase in its cost of revenue, peaking at approximately $87 million in 2022, a 15-fold increase from 2014. This growth reflects their expanding operations and market reach.
Conversely, Dyne Therapeutics experienced a dramatic fluctuation. Starting with a high cost of $1.1 billion in 2014, it plummeted to a mere $24,000 in 2018, before stabilizing around $2.5 million in 2023. This volatility highlights the challenges and strategic shifts within the company.
These insights underscore the dynamic nature of the biopharmaceutical industry, where strategic decisions and market conditions significantly impact financial outcomes.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Walgreens Boots Alliance, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: CRISPR Therapeutics AG vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.